OncoMatch/Clinical Trials/NCT04834544

A Study of Maintenance DCVAC/OvCa After First-line Chemotherapy Added Standard of Care

Is NCT04834544 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies DCVAC/OvCa for epithelial ovarian carcinoma.

Phase 2RecruitingPeking University Third HospitalNCT04834544Data as of May 2026

Treatment: DCVAC/OvCa — This is a randomized, double-blind, placebo-controlled,parallel-group preliminary verifying study about safety and efficacy of maintenance DCVAC/OvCa after first-line chemotherapy added to standard of care in patients with newly diagnosed FIGO III-IV ovarian, fallopian tube, or primary peritoneal carcinoma.

Check if I qualify

Extracted eligibility criteria

Cancer type

Ovarian Cancer

Biomarker criteria

Required: BRCA1 any mutation

Required: BRCA2 any mutation

Disease stage

Required: Stage III, IV

Grade: high-grade seroushigh-grade endometrioid

Performance status

ECOG 0–2(Ambulatory, capable of self-care)

Prior therapy

No prior treatment (treatment-naive required)

Max 0 prior lines

Cannot have received: platinum-based chemotherapy

Exception: already started after surgery

First-line Pt-based adjuvant chemotherapy already started after surgery

Cannot have received: radiation therapy

Exception: previous or concurrent radiotherapy to the abdomen and pelvis

Previous or concurrent radiotherapy to the abdomen and pelvis

Cannot have received: immunotherapy

Use of any immunotherapy in the past (e.g., anti-PD-1/PD-L1 or other immune checkpoint inhibitors, therapeutic vaccines, adoptive cell therapy, cytokines)

Lab requirements

Blood counts

WBC >4000/mm3; neutrophil count >1500/mm3; hemoglobin ≥8 g/dL; platelet count ≥100,000/mm3

Kidney function

Serum creatinine <2× ULN; blood urea nitrogen <2× ULN

Liver function

Total bilirubin <2× ULN (benign hereditary hyperbilirubinemias permitted); ALT, AST <2× ULN

Cardiac function

No clinically significant cardiovascular disease (see exclusion 10.4); ejection fraction <40% excluded

Laboratory criteria: WBC >4000/mm3; neutrophil count >1500/mm3; hemoglobin ≥8 g/dL; platelet count ≥100,000/mm3; total bilirubin <2× ULN (benign hereditary hyperbilirubinemias permitted); ALT, AST, creatinine <2×ULN; blood urea nitrogen <2×ULN. Adequate coagulation parameters: aPTT ≤1.5×ULN; INR ≤1.5

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify